Today announced that the Brain Tumor Research Middle at the University of California.

today announced that the Brain Tumor Research Middle at the University of California, San Francisco, has begun enrolling individuals into a Phase 2 medical trial of Oncophage in combination with the standard of care – radiation therapy plus Temodar – for newly diagnosed glioma sufferers. The overall goals of the investigator-sponsored research are to evaluate median general survival, progression-free survival and immunologic response to vaccine treatment. Parsa, MD, PhD, associate professor in the department of neurological surgery at the University of California, San Francisco, and principal investigator of the trial.5 months. Patients shall undergo surgery to eliminate their tumors, which are after that used to produce their patient-specific vaccines.Related StoriesHealthcare technology public event of the entire year opens entriesDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of PolyphotonixCombatting viral and bacterial lung attacks with volatile anesthetics: an interview with Dr ChakravarthyWhen wanting to assess the effectiveness of an intervention it’s quite common practice that sufferers whose post-treatment pain scores are lower than their pre-treatment scores are categorized as having undergone effective treatment.